

November 11, 2020

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Wednesday, November 11, 2020

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we Zota Health Care Limited (the "Company") would like to inform you that the Board of Directors of the Company in its Meeting held on Wednesday, November 11, 2020 at 02:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002 have, *inter alia*, discussed and approved following businesses:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2020 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure – I).

Unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com

2. Appointed Mr. Ashvin Variya, the Company secretary & Compliance officer of the Company as the Nodal Officer of the Company for the purpose of verification of claim(s) and coordination with Investor Education and Protection Fund Authority.

The Board meeting concluded at 4:55 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya

(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com

Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122



CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter and half year ended September 30, 2020** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.



CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

> CA. Shivangi Mehta Proprietor


> > M. No.118936

UDIN: 20118936AAAADD8409

Date: 11/11/2020 Place: Surat

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002 SURAT



14	healthcare Itd.		Quarter Ended			(₹ in Lakhs, except per share dat		
	Particulars	30-09-2020 30-06-2020 30-09-2019			Half Year Ended Year E 30/09/2020 30/09/2019 31-03-			
		(Unaudited)		(Unaudited)	(Unaudited)	(Unaudited)	31-03-2020	
						(onauditeu)	(Audited)	
l.	Revenue from Operations	2816.64	1754.96	2528.75	4571.60	4505.04	20000	
II.	Other Incomes	21.14	22.82	37.49	43/1.60	4696.94	9511.2	
III.	Total Revenue			37.4	43.55	67.30	151.3	
		2837.78	1777.78	2566.24	4615.55	4764.24	9662.57	
IV.	Expenses:					7		
	Cost of Materials Consumed:	348.78	223.44	179.70	F72.22	502.00		
	Purchases of Stock-in-Trade	1708.73	1682.71	1451.28	572.23	542.15	1303.9	
	Changes in Inventories of Finished Goods, Work-in-Progress and	1 2 1 10 2 7 E	1002.71	1431.20	3391.44	2498.86	4617.40	
1	Stock-in-Trade	(186.02)	(741.83)	163.86	(927.85)	252.22		
	Employee Benefit Expenses	236.81	206.50	258.99	443.31	253.33 502.50	708.70	
	Finance Costs	1.48	0.74	1.02	2.23		1034.05	
	Depreciation / Amortisation and Depletion Expense	76.63	73.91	32.05	150.54	2.32 62.08	6.91 209.75	
	Other Expenses	623.10	269.05	222.04			205.75	
-	Total Expenses	2809.53	268.95	332.94	892.06	672.80	1393.81	
		2809.53	1714.43	2419.84	4523.95	4534.06	9274.55	
V.	Profit before Exceptional items and tax from continuing operations							
10	(III-IV)	28.25	63.35	146.40	04.50			
	Exceptional Items	102.88	03.55	140.40	91.60	230.18	388.02	
	Profit/(loss) before tax	131.13	63.35	146.40	102.88 194.48	222.42	400.00	
	Tax Expense:	1		240.40	134.40	230.18	388.02	
	1) Current tax	31.40	18.30	36.81	49.70	57.88	103.53	
1	1.1) I.T. & DD Tax Provision Created Short/ excess 2) Deferred Tax	-	-	-		0.26	2.07	
1	2) beieffed tax	2.01	5.79	(0.49)	7.80	(6.75)	(6.40)	
IX. P	Profit/ (Loss) for the period from Continuing						,,,,,,,,,	
	Operations (VII-VIII)	404 74	55-2.74	10.00				
_	rofit/(loss) before tax from discontinued operations	101.74	50.84	109.11	152.58	165.28	276.01	
XI. T	ax Expense of discontinued Operations	31	-	-	-	-		
XII. P	rofit / / cas from B:	9	-	1.0		1.5		
0	rofit/ (Loss) from Discontinued Operations (after Tax)							
	rofit/ (Loss) for the period	401.01			9		-	
	ther Comprehensive Income	101.74	50.84	109.11	152.58	165.28	276.01	
Α	(i) Items that will not be reclassified to Statement of							
	profit and loss	14.68	(2.47)		1	1110		
	(ii) Income Tax relating to items that will not be	14.08	(3.47)	4.59	11.21	16.09	16.46	
	reclassified to Statement of profit and loss	(3.69)	0.87	12 251	/2.001	1000		
В	(i) Items that will be reclassified to Statement of profit	10.007	0.07	(1.15)	(2.82)	(4.05)	(4.14)	
- 44	and loss	-	-					
	(ii) Income Tax relating to items that will be reclassified to profit and loss				1	1	-	
Ot	ther comprehensive income for the period, net of tax	200	Fa 535	-				
To	otal comprehensive income for the period (XIII + XIV)	10.98	(2.60)	3.43	8.39	12.04	12.32	
		112.72	48.24	112.54	160.96	177.32	288.33	
	id-up Equity Share Capital	2456.03	2456.03	2456.03	2456.03	2456.03	2456.03	
	her Equity			1 477 - 377		2730.03	4429.06	
(1)	rnings per equity share of face value of ` 10 each Basic (in `)		3.5				4429.00	
	Diluted (in ')	. 0.41	0.21	0.44	0.62	0.67	1.12	
	potes figures less than a lakh	0.41	0.21	0.44	0.62	0.67	1.12	

For and on behalf of the Board

(Whole Time Director)

Himanshu M. Zota (Din: 01097722)

(Managing Director)

Moxesh K. Zota

(Din: 07625219)

Company Secretary Chief Financial Officer Viral Mandviwala

Date: 11/11/2020

Ashvin Variya

Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

For Shivangi Parekh & Co. **Chartered Accountants**

Pare

ed ACO

CA. Shivangi Mehta Proprietor M. No. 118936

Firm No. 131449W

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") **and its subsidiaries** (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and half year ended September 30, 2020** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

CHARTERED ACCOUNTANTS

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total assets of Rs. 9.19 Lakhs as at September 30, 2020, total revenues of Rs.0.14 Lakhs and 0.23 Lakhs, total net profit after tax of Rs. 0.14 Lakhs and 0.17 Lakhs and total comprehensive income of Rs.0.14 Lakhs and Rs. 0.17 Lakhs, respectively for the quarter and half year ended September 30, 2020, and net cash flows of Rs. 0.85 Lakhs for the half year ended September 30, 2020 as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Date: 11/11/2020

Place: Surat

For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

> CA. Shivangi Mehta Proprietor

> > M. No.118936

UDIN: 20118936 AAAADE 1345



	nealthcare Itd.		Quarter Ended			(₹ in Lakhs, except Half Year Ended	
	Particulars	30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-20
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited
l.	Revenue from Operations	2816.64	1754.96	2528.75	4571.60	4696.94	9511.
II.	Other Incomes	21.10	23.08	37.49	44.19	67.30	151
ш.	Total Revenue	2837.74	1778.04	2566.24	4545.70	****	
IV.	Expenses:	2037.74	1770.04	2500.24	4615.79	4764.24	9662
	Cost of Materials Consumed:	348.78	223.44	170 70		-2/0/44	
	Purchases of Stock-in-Trade	1708.73	1682.71	179.70 1451.28	572.23 3391.44	542.15 2498.86	1303
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-			2132.20	3331,44	2430.00	4617
	in-Trade Employee Benefit Expenses	(186.02)	(741.83)	163.86	(927.85)	253.33	708
	Finance Costs	236.81 1.48	206.50 0.74	258.99	443.31	502.50	1034
	Depreciation / Amortisation and Depletion Expense	76.63	73.91	1.02 32.05	2.23	2.34	6
	Other Expenses	623.10	269.01	332.98	150.54 892.12	62.08 672.84	1395
	Total Expenses	2809.53	1714.49	2419.88			
v.	Profit before Exceptional items and tax from continuing operations	2003.33	1/14.43	2419.88	4524.01	4534.11	9276
	(III-IV)	28.22	63.56	146.36	01 77	220.12	
VI	Exceptional Items	102.88	- 03.30	140.36	91.77 102.88	230.13	386
/11.	Profit/(loss) before tax	131.10	63.56	146.36	194.65	230.13	386
/111.	Tax Expense: (1) Current tax	50.00					500
	(1.1) I.T. & DD Tax Provision Created Short/ excess	31.40	18.30	36.81	49.70	57.88	103
	(2) Deferred Tax	2.01	5.79	(0.49)	7.80	0.26	2
x.	Profit/ (Loss) for the period from Continuing	1.836		(0.43)	7.60	(6.75)	(6
	Operations (VII-VIII)	101.71	51.05	109.07	152.75	165.23	274
۲.	Profit/(loss) before tax from discontinued operations	2271.2	52.05	105.07	132.73	105.25	274
a.	Tax Expense of discontinued Operations			1			
II.	Profit/ (Loss) from Discontinued Operations (after Tax)	* 1	1	1	-	7	
	(X-XI)						
ш.	Profit/ (Loss) for the period	101.71	51.05	109.07	152.75	165.23	274.
IV.	Other Comprehensive Income	110211101		200.07	132.73	103.23	2/4
	A (i) Items that will not be reclassified to .Statement of profit and loss		4000			0.00	
	(ii) Income Tax relating to items that will not be	14.68	(3.47)	4.59	11.21	16.09	16
	reclassified to Statement of profit and loss	(3.69)	0.87	(1.15)	(2.82)	(4.05)	(4
	B (i) Items that will be reclassified to Statement of profit and loss				,,	(1.05)	1.
	(ii) Income Tax relating to items that will be reclassified	*	*	(0.09)		(0.09)	
	to profit and loss		*				
	Other comprehensive income for the period, net of tax	10.99	(2.60)	2.24	0.00		
	Total comprehensive income for the period (XIII + XIV)	112.70	48.44	3.34 112.41	8.39 161.14	11.95	12. 286.
- 1	Profit attributable to:			100.00	200	5,1,55	
	Owners of the parent	101.71	51.05	100.07	250.00	0.00	00.5
	Non-controlling interest	-	51.05	109.07	152.75	165.23	274.
	Other comprehensive income attributable to:						
	Owners of the parent	10.99	(2.60)	3.34	8.39	11.05	12
	Non-controlling interest	-		-	0.55	11.95	12.:
	Total Comprehensive Income attributable to:						
	Owners of the parent	112.70	48.44	112.41	161.14	177.10	
	Non-controlling interest		70.44	112.41	161.14	177.18	286.
	Paid-up Equity Share Capital		2012 Cal				
	Other Equity	2456.03	2456.03	2456.03	2456.03	2456.03	2456.0
							4426.8
	arnings per equity share of face value of ` 10 each						
	1) Basic (in ')	0.41	0.21	0.44			

denotes figures less than a lakh For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota (Din: 01097722)

Moxesh K. Zota (Din: 07625219)

Company Secretary Ashvin Variya Chief Financial Officer Viral Mandviwala

Registered Office ate: 11/11/2020

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin,

Surat - 394 230 (Guj.) India Ph: +91 261 2397122

SURAT

CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W

For Shivangi Parekh & Co.



Notes:

- 1. The above financial results for the quarter and half year ended September 30, 2020 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 11, 2020.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2020.
- 4. During the reporting period, the Company has sold the open industrial plot situated at Hojiwala Industrial Estate, Surat at the consideration of Rs. 108.42 lakhs. The said industrial plot was purchased back in the year 2004 for the purpose of establishment of warehouse/ factory. But due to non-viable circumstances it was not done. The said industrial plot remained unutilized since then. Profit on sale of the said plot has been reported under the head exceptional item in the Statement of profit and loss of the Company.
- 5. The Company continuously monitoring the impact of COVID-19 on Company's business. The Company has done assessment of its liquidity position and expects to fully recover the carrying amount of receivables, investments, intangible assets and other assets. The Company has also evaluated the inventory in hands and found it's sufficient to honor future orders.
- 6. The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
- 7. The consolidated results include the result of following wholly owned subsidiaries:
 - Zota Healthcare Lanka (Pvt) Ltd.
 - ii) Davaindia Health Mart Limited
- 7 8. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.



Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com

Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 39'4 230 (Guj.) India Ph: +91 261 2397122



ZOTA HEALTH CARE LIMITED Unaudited Cash Flow Statement For the Half Year Ended 30th September, 2020

Amounts ₹ in Lakhs Consolidated Standalone Half year Half year ended Half year ended Half year ender **PARTICULARS** 30-09-2020 30-09-2019 30-09-2020 30-09-2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) CASH FLOW FROM OPERATING ACTIVITIES Net Profit Before Tax as per Statement of Profit and Loss 194.65 230.13 194.48 230.18 Adjusted for: Exceptional items -102 88 -102.88 Depreciation / Amortisation and Depletion Expense 150 54 62.08 150.54 62.08 Interest on Fixed Deposits -41.53 -54 93 -41.30 -54.93 Interest - others -0.47 0.23 -0.47 0.23 **Operating Profit before Working Capital Changes** 200.31 237.52 200.37 237.57 Adjusted for: Trade Payables 716 51 220.98 220.98 **Provisions-Current Liabilities** 70.14 105.61 106.03 **Borrowings-Current Liabilities** 0.00 0.00 0.00 0.00 Provisions - Non-Current 4.63 1.04 4.63 0.67 **Current Liabilities** 41.39 76.90 41.39 76.03 Trade Receivables 103.16 -487.27 103.16 -487.27 Loans 61.58 -126.65 62.86 -126.65 Inventories -1002.96 359 00 -1002.96 359.00 Other Current Assets -193.62 -117.72 -193.62 -117.72 **Changes in Working Capital** -199.16 31.90 -197.35 31.08 Cash Generated from Operations 1.15 269.41 3.03 268.65 Net Cash Flow from/(Used in) Operating Activities (A) -51.37 207.22 -49.49 CASH FLOW FROM INVESTING ACTIVITIES Purchase of Intangible Assets -8.17 0.00 -8.17 0.00 Decrease in Long Term Loans & Advances 2.50 2.47 2.50 2.47 Interest on Fixed Deposits 41.53 54.93 41.30 54.93 Interest on GEB Deposits 0.47 -0.23 0.47 -0.23 Proceeds from disposal of Property, Plant and Equipment 108.42 108.42 Purchase of Tangible Assets -65.05 -56.42 -65 05 -56 42 Non-current Investments 234.86 45.74 243.09 45.74 Net Cash Flow (Used in) Investing Activities (B) 314.57 46.49 322.57 46.49 CASH FLOW FROM FINANCING ACTIVITIES Add: Adjustment for

(C)

(A+B+C)

263.20

83.49

346.68

The accompanying notes are an integral part of the financial statements. As per our report of even date

iging Director

Moxesh K. Zota

(Din: 07625219)

8D,Lal Bunglow,

Surat.

Net Cash Flow from / (Used in) Financing Activities

Net Increase/(Decrease) in Cash & Cash Equivalents

Opening Balance of Cash and Cash Equivalents

Closing Balance of Cash and Cash Equivalents

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota (Din: 01097722) 34,Ichhanath Umra.

Dividend Paid

Tax on Dividend

Ashvin Variya

Viral Mandviwala (Company Secretary) (Chief Financial Officer)

Date: 11/11/2020 Place: Surat

For Shivangi Parekh & Co. **Chartered Accountants**

273.07

72.76

345.83

-245 60

-50.49

-296.10

-43.15

169.43

126.27

-245.60

-50.49

-296.10

-42.39

169.43

127.04

CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W



Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122



ZOTA HEALTH CARE LIMITED

Standalone and Consolidated Statement of Assets and Liabilities

		Standa	lone	Amounts ₹ in Lakhs Consolidated		
	Particulars	As at	As at	As at	As at	
		30th September 2020 Unaudited	31st March, 2020 Audited	30th September 2020 Unaudited	31st March, 2020 Audited	
	ASSETS		Addited	Ollaudited	Audited	
(1)	Non-Current Assets					
	Property, plant and equipment	766.10	803.24	766.10		
	Intangible Assets	691.14	737.55	691.14	803.2	
	Capital work-in-progress	0.68	757.55	1000000	737.5	
	Intangible assets under development	0.00		0.68		
	Financial Assets					
	(i) Investments	1160.16	1403.25	1157.60	72.22	
	(iii) Loans	25.68	28.18	25.68	1392.4	
	Other Non-current assets	25.00	20.10	25.68	28.2	
	Total Non-Current assets	2643.76	2972.22	2641.20	2961.4	
(2)	Current Assets		9.77			
	Inventories	3537.04	2534.08		1000	
	Financial Assets	3537.04	2534.08	3537.04	2534.0	
	(i) Trade Receivables	2810.48	2012 05	22700		
	(ii) Cash and Cash Equivalents	1.54	2913.65	2810.48	2913.6	
	(iii) Bank balance other than cash and cash	1.54	1.42	1.54	1.4	
	equivalents	30200	7.14			
	(iv) Loans	344.28	71.33	345.14	82.0	
	Other Current Assets	257.16	320.01	257.16	318.7	
	Total Current assets	230.02	36.40	230.12	36.5	
	Total Assets	7180.53	5876.90	7181.48	5886,4	
	TOTAL PUBLIC	9824.28	8849.12	9822.68	8847.8	
	EQUITY AND LIABILITIES		0			
1)	Equity					
	(i) Equity Share capital	2456.03	2456.03	2456.03	2456.0	
	(ii) Other Equity	4590.02	4429.06	4588.01	4426.8	
	Total Equity (Refer Note 1)	7046.06	6885.09	7044.04	6882.9	
2)	Liabilities					
-,	Non-Current Liabilities					
	Financial Liabilities					
	(i) Borrowings		1			
	Provisions	7.				
	Deferred tax liabilities (Net)	92.09	87.47	92.09	87.4	
	Total non-current liabilities	10.07	17.87	10.07	17.8	
	Total non-current nabilities	102.16	105.34	102.16	105.34	
	Current liabilities	30				
	Financial Liabilities					
	(i) Borrowings	4.1				
	(ii) Trade payables	2.1	1 2			
	- Total oustanding dues of micro enterprises and small					
	enterprises	183.29	205.61	102.20	100	
	- Total Oustanding dues of Creditors other than micro	103.23	205.01	183.29	205.61	
	enterprises and small enterprises	2032.25	1293.04	2022 25	1225 40	
	Other Current liabilities	205.48	164.10	2032.35	1293.52	
	Provisions	255.04	The same of the sa	205.49	164.10	
	Total current liabilities	2676.07	195.95	255.35	196.41	
	Total Liabilities	2778.23	1858.69	2676.48	1859.64	
	Total Equity and Liabilities	9824.28	1964.03	2778.64	1964.98	
	The state of the s	3024.28	8849.12	9822.68	8847.88	

Since the subsidiary companies are Wholly Owned Subsidiaries, the non controlling interests is Nil in case of Consolidated Financial Statements and thus, Equity attributable to owners of the Company shall be the same as total equity.

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota

(Din: 01097722)

(Managing Director) Moxesh K. Zota (Din: 07625219)

Ashvin Variya

Company Secretary Chief Pinancial Officer Viral Mandviwala

Date: 11/11/2020 Place : Surat

For Shivangi Parekh & Co. Chartered Accountants Parek

SURAT

vangi Mehta Proprietor M. No. 118936

firm No. 131449W

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122